target the EGFR mutation gefitinib, erlotinib and Afatinib e all positive for PFS and all negative for OS because of crossover. If OS had been the only endpoint, all these drugs would still not be on our pharmacy shelves. So I believe if you have a great treatment that should activity very early on then PFS should be the endpoint. However if the benefit is small but still significant then OS must be the endpoint. But surely at this point in time we only want very active treatments that give us big differences in PFS as we know that these will be the treatments that can change lives.
The aim of an anticancer treatment in palliative setting, i.e. when there is no curative intent, is to improve the quantity and the quality of life. The evaluation of a treatment effect is mainly based on randomized clinical trials which are meant to provide a correct assessment of the effect size. Therefore, the selection of the primary endpoint is critical not only for the sample size calculation but mainly to judge the relevance and the meaning of the treatment results which define the treatment utility from both the patient perspective and the healthcare system in terms of cost-effectiveness. Two categories of endpoints are used in clinical trials: some are patient-centered, clinical endpoints including overall survival (OS), health-related quality of life (HRQoL) assessment and tolerance profile whereas other are tumor-centered as progression-free survival (PFS), response rate, disease control rate. OS is a universally accepted measure of the treatment benefit in oncology, directly reflecting the quantity of life gained and is still the preferred endpoint of Phase III clinical trials. However, OS as a primary endpoint has some limitations: it usually requires a longer follow-up and a large sample size leading to an increase in the cost of trials. Moreover, especially in cancer with an improved prognosis as for lung cancer depending on an oncogenic driver, OS can be confounded by the effect of crossover and subsequent treatments with small expected OS differences between treatment sequences. These reasons make increasingly difficult to demonstrate an OS benefit especially for first-line therapy. These limitations have led to consider tumor-centered endpoints, mainly PFS, as surrogate endpoints for patient benefit in a clinical trial. PFS provides results earlier than OS and is not influenced by subsequent treatments. However, selecting PFS as primary endpoint assumes that there is a statistical validation of PFS as a surrogate endpoint for OS, which is not the case in advanced NSCLC, especially in palliative setting: many trials have demonstrated a PFS benefit without improvement of OS. Furthermore, there is a lack of consensus for PFS definition or tumor progression (i.e. taking or not into consideration symptomatic progressions), blinding or independent review is required to provide more robust evidence of a PFS benefit and its assessment is dependent on the schedule of tumor evaluations. In this context, HRQoL may constitute an alternative endpoint, which ensures earlier assessment of direct clinical benefit for the patient and takes into account the impact of potential treatment-related toxicities; HRQoL is therefore more recognized as a component endpoint for assessment of the benefit coming from cancer therapy by the American Society of Clinical Oncology and the European Society of Medical Oncology and for drug approval by Regulatory Agencies. It appears obvious that a delay in the time to symptom deterioration, or improvements in symptoms and in HRQoL might be more meaningful to the patient with an advanced lung cancer than the RECIST criteria or PFS, not necessarily reflecting a clinically meaningful benefit. HRQOL is a multidimensional concept representing the patient's perception of the effect of illness and treatment on physical, psychological, and social aspects of life. QoL measurement in clinical trials is based upon patient reported outcome (PROs) which are reports of the status of a patient's health condition coming directly from the patient, without any interpretation by a clinician. Many validated self-completion QoL questionnaires for cancer patients are available, taking into consideration the multidomain aspect of QoL; the EORTC QLQ-C30 with its specific module for lung cancer (LC-13), the FACT-L are the most frequently used for assessment of patients HRQL, physical functioning, or tumor related symptoms in lung cancer. HRQoL evaluated with PROs has been shown to be an independent prognostic factor in advanced lung cancer. However, the complexity and heterogeneity of QoL data reports and numerous methodological issues for QoL analyses make the PROs difficult to understand for clinicians and limit their utility to help for therapeutic decisions. Indeed, HRQoL is challenging to assess and raises many methodological issues, including missing data and patient drop-out rate, multiplicity, longitudinal analysis and lack of standardization making impossible to perform cross trials comparisons. These issues as well as the usual deferred publication of QoL results after tumorcentered endpoints communication have led the scientific community and the clinicians to give little attention to PROs. Nevertheless, there is a greater awareness that a similar degree of scientific rigor should be applied to the PRO strategy to make it a key component of treatment effect, likely more sensitive to assess therapy's effect on the disease and the patient than conventional measures. Different approaches have been underscored to improve the use of PROs in clinical trials. Recent extensions of the CONSORT have suggested recommendations for PROs analysis and report in clinical trials, with the need to define PROs as a primary or secondary endpoint with a specific statistical defined hypothesis, including approaches to deal with missing data; it is then possible to consider HRQoL as a co-primary endpoint. New statistical methods have also been suggested for longitudinal analyses of PROs as linear mixed model for repeated measures or time until definitive deterioration for symptoms or QoL score deterioration. Other approaches suggest focusing on three well-defined concepts: symptomatic adverse events, physical function, and disease-related symptoms which are easier to assess and are key components of a treatment effect. Information after the treatment and during subsequent treatment should also be collected to take into consideration the impact of a delayed disease progression on QoL or those of subsequent treatment or residual toxicities. As tremendous advances have been made in the field of lung cancer treatment, especially in advanced disease with its transformation into a chronic disease for some patients, the treatment focus has shifted to improve or preserve the patients QoL. It is therefore mandatory to develop new and validated endpoints that better indicate a clinical benefit rather than small variations in tumor size. PROs should not be viewed anymore as a surrogate endpoint, but regarded as an important patient-centered endpoint, needing an optimization of trials design and methods to analyze HRQoL. Keywords: Patient-reported outcome, clinical trials, lung cancer PC05.07 Let's Not Forget Chemo-Regret P. Hollen University of Virginia, Charlottesville, VA/US Background: Although thousands of patients annually receive treatment for advanced non-small cell lung cancer (NSCLC), little is known about their views on the decision to receive that treatment. Even with encouraging newer treatments, survival rates continue to be low in NSCLC. With potential treatment toxicities and with modest response rates, there are many risks for regret by both patients and their supporters. The highly symptomatic nature of NSCLC, coupled with pressures to decide rapidly on therapy, creates challenges that affect quality decision making. In a recent review of 59 studies dealing with regret (Becerra Perez et al, Med Decis Making; 2016; 36:777-790) , no study focused on lung cancer, even with 66% of the studies in oncology settings, none reported reduced regret over time during the study, and only 2 studies reported delayed regret several months after the
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